Literature DB >> 9062411

Synergistic antiproliferative activity of tamoxifen and docetaxel on three oestrogen receptor-negative cancer cell lines is mediated by the induction of apoptosis.

C Ferlini1, G Scambia, M Distefano, P Filippini, G Isola, A Riva, E Bombardelli, A Fattorossi, P Benedetti Panici, S Mancuso.   

Abstract

The taxanes are a promising family of anti-tumour drugs that block cell cycle replication by interfering with the microtubule network. The clinical use of these drugs involves some problems related to their low solubility and occurrence of resistance, which is mainly dependent on the multidrug-resistant (MDR) phenotype. To investigate the possible interaction between docetaxel and tamoxifen (TAM), three oestrogen receptor-negative cancer cell lines, MDR- MDA-MB 231, MDR + CEM-VBLr and MCF-7 ADRr, were used. In all three cell lines, the combination of docetaxel and TAM was more effective in terms of growth inhibition than single drug exposure. Isobolic analysis confirmed the presence of synergism in all cell lines when docetaxel was used at 0.2 microM and TAM at a dose equal to or higher than 1 microM. Flow cytometric DNA analysis performed on the three cell lines showed that TAM was able to increase the G2/M blocking activity of docetaxel. This blocking activity was followed by an increased flow cytometric DNA fragmentation suggestive of the presence of apoptosis, which was confirmed by DNA gel fragmentation and morphological analysis. While an antagonistic effect on P-glycoprotein (P-gp) activity may contribute to the synergistic effect of tamoxifen and docetaxel on CEM-VBLr and MCF-7 ADRr, other mechanisms must be involved, as the synergistic effect is also apparent with a P-gp-negative cell line.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9062411      PMCID: PMC2063403          DOI: 10.1038/bjc.1997.156

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  22 in total

1.  Opposite effects of tamoxifen on in vitro protein kinase C activity and endogenous protein phosphorylation in intact MCF-7 cells.

Authors:  M Issandou; C Faucher; F Bayard; J M Darbon
Journal:  Cancer Res       Date:  1990-09-15       Impact factor: 12.701

2.  Reversal of acquired resistance to doxorubicin in P388 murine leukemia cells by tamoxifen and other triparanol analogues.

Authors:  A Ramu; D Glaubiger; Z Fuks
Journal:  Cancer Res       Date:  1984-10       Impact factor: 12.701

3.  Promotion of microtubule assembly in vitro by taxol.

Authors:  P B Schiff; J Fant; S B Horwitz
Journal:  Nature       Date:  1979-02-22       Impact factor: 49.962

4.  Ca2(+)-dependent binding of tamoxifen to calmodulin isolated from bovine brain.

Authors:  M C Lopes; M G Vale; A P Carvalho
Journal:  Cancer Res       Date:  1990-05-01       Impact factor: 12.701

5.  Synergistic antiproliferative activity of tamoxifen and cisplatin on primary ovarian tumours.

Authors:  G Scambia; F O Ranelletti; P Benedetti Panici; M Piantelli; R De Vincenzo; G Bonanno; G Ferrandina; G Isola; S Mancuso
Journal:  Eur J Cancer       Date:  1992       Impact factor: 9.162

6.  Steroid receptor-mediated cytotoxicity of an antiestrogen and an antiprogestin in breast cancer cells.

Authors:  S Bardon; F Vignon; P Montcourrier; H Rochefort
Journal:  Cancer Res       Date:  1987-03-01       Impact factor: 12.701

7.  Enhancement of the antiproliferative effect of cis-diamminedichloroplatinum(II) and nitrogen mustard by inhibitors of protein kinase C.

Authors:  J Hofmann; W Doppler; A Jakob; K Maly; L Posch; F Uberall; H H Grunicke
Journal:  Int J Cancer       Date:  1988-09-15       Impact factor: 7.396

8.  The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma.

Authors:  E F McClay; M J Mastrangelo; J D Sprandio; R E Bellet; D Berd
Journal:  Cancer       Date:  1989-04-01       Impact factor: 6.860

9.  Quercetin inhibits the growth of a multidrug-resistant estrogen-receptor-negative MCF-7 human breast-cancer cell line expressing type II estrogen-binding sites.

Authors:  G Scambia; F O Ranelletti; P Benedetti Panici; M Piantelli; G Bonanno; R De Vincenzo; G Ferrandina; L Pierelli; A Capelli; S Mancuso
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

10.  Effect of tamoxifen on cell lines displaying the multidrug-resistant phenotype.

Authors:  E Berman; M Adams; R Duigou-Osterndorf; L Godfrey; B Clarkson; M Andreeff
Journal:  Blood       Date:  1991-02-15       Impact factor: 22.113

View more
  8 in total

Review 1.  Docetaxel: an update of its use in advanced breast cancer.

Authors:  D P Figgitt; L R Wiseman
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

2.  Conjugation of pH-responsive nanoparticles to neural stem cells improves intratumoral therapy.

Authors:  Rachael Mooney; Yiming Weng; Elizabeth Garcia; Sukhada Bhojane; Leslie Smith-Powell; Seung U Kim; Alexander J Annala; Karen S Aboody; Jacob M Berlin
Journal:  J Control Release       Date:  2014-06-18       Impact factor: 9.776

3.  CYP1A1 is overexpressed upon incubation of breast cancer cells with a polyphenolic cocoa extract.

Authors:  Carlota Oleaga; Miriam García; Anna Solé; Carlos J Ciudad; Maria Izquierdo-Pulido; Véronique Noé
Journal:  Eur J Nutr       Date:  2011-08-06       Impact factor: 5.614

4.  Systematic expression analysis of genes related to multidrug-resistance in isogenic docetaxel- and adriamycin-resistant breast cancer cell lines.

Authors:  Wen-Jing Li; Shan-Liang Zhong; Yuan-Jian Wu; Wei-Dong Xu; Jin-Jin Xu; Jin-Hai Tang; Jian-Hua Zhao
Journal:  Mol Biol Rep       Date:  2013-11       Impact factor: 2.316

5.  ERRα Is a Marker of Tamoxifen Response and Survival in Triple-Negative Breast Cancer.

Authors:  Subrata Manna; Josefine Bostner; Yang Sun; Lance D Miller; Anya Alayev; Naomi S Schwartz; Elin Lager; Tommy Fornander; Bo Nordenskjöld; Jane J Yu; Olle Stål; Marina K Holz
Journal:  Clin Cancer Res       Date:  2015-11-05       Impact factor: 12.531

6.  A new role for tamoxifen in oestrogen receptor-negative breast cancer when it is combined with epigallocatechin gallate.

Authors:  M J Scandlyn; E C Stuart; T J Somers-Edgar; A R Menzies; R J Rosengren
Journal:  Br J Cancer       Date:  2008-09-16       Impact factor: 7.640

7.  In silico identification of drug target pathways in breast cancer subtypes using pathway cross-talk inhibition.

Authors:  Claudia Cava; Gloria Bertoli; Isabella Castiglioni
Journal:  J Transl Med       Date:  2018-06-05       Impact factor: 5.531

8.  Tamoxifen induces oxidative stress and apoptosis in oestrogen receptor-negative human cancer cell lines.

Authors:  C Ferlini; G Scambia; M Marone; M Distefano; C Gaggini; G Ferrandina; A Fattorossi; G Isola; P Benedetti Panici; S Mancuso
Journal:  Br J Cancer       Date:  1999-01       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.